Across populations, somatic mutations in TP53 are more common in TNBC and HER2+ tumors; conversely, somatic mutations in PIK3CA are much more frequent in ER-positive (ER+) tumors and luminal breast cancers (2, 4). This evidence concerns the gene ERBB2 and breast cancer.